Supernus Pharmaceuticals filings document regulatory disclosures for a Nasdaq-listed biopharmaceutical company focused on central nervous system diseases. Recent Form 8-K reports cover operating results, conference-call related earnings releases, material definitive agreements, executive compensation arrangements, and other material events tied to the company's CNS product portfolio and corporate obligations.
Proxy materials describe annual meeting voting matters, director elections, advisory executive compensation votes, auditor ratification, and equity incentive plan amendments. The filings also identify the company's common stock structure, exchange listing, shareholder voting mechanics, governance practices, and capital-structure disclosures.
Supernus Pharmaceuticals director Charles W. Newhall III reported equity awards consisting of 2,989 restricted stock units and options for 4,977 shares, both granted on February 18, 2026. Each restricted stock unit converts into one share, and both the RSUs and options vest on February 18, 2027.
Hudson Frederick M. reported acquisition or exercise transactions in this Form 4 filing.
SUPERNUS PHARMACEUTICALS, INC. director Frederick M. Hudson reported equity awards consisting of restricted stock units and stock options. He was granted 2,989 restricted stock units and 4,977 director stock options on February 18, 2026, each at a grant price of $0 per unit or option.
Each restricted stock unit represents one share of Supernus common stock and will be settled in common stock when it vests on February 18, 2027. The stock options also vest on February 18, 2027, giving him the right to buy Supernus common stock in the future, subject to the option terms.
Supernus Pharmaceuticals, Inc. Schedule 13G/A reports beneficial ownership disclosures by investment managers and a principal. Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander are each shown with 5.7% of common stock, equivalent to 3,281,615 shares. Integrated Core Strategies (US) LLC is shown with 4.9%, equivalent to 2,817,883 shares. The filing is a joint filing under a February 17, 2026 Joint Filing Agreement.
Supernus Pharmaceuticals Schedule 13G/A shows Armistice Capital, LLC and Steven Boyd report beneficial ownership of 2,764,000 shares, equal to 4.82% of the common stock as of 12/31/2025. The filing states Armistice Capital exercises voting and investment power under an Investment Management Agreement, while the Master Fund disclaims beneficial ownership.
Supernus Pharmaceuticals, Inc. filed a Form 8-K to announce when it will release its next financial update. The company expects to report fourth quarter and full year 2025 financial and business results after the market closes on Tuesday, February 24, 2026.
Management, including the President and CEO Jack Khattar and Senior Vice President and CFO Tim Dec, will host a conference call and webcast on February 24, 2026 at 4:30 p.m. ET to discuss these results and answer questions. A live webcast and a 60-day replay will be available through the Investor Relations section of the company’s website.
Supernus Pharmaceuticals, Inc. received a Schedule 13G filing showing that Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander collectively report beneficial ownership of 3,036,123 shares of Supernus common stock. This represents 5.3% of the outstanding common shares as of the event date.
The reporting persons have shared voting and dispositive power over all 3,036,123 shares, with no sole voting or dispositive power. They certify that the shares were not acquired for the purpose of changing or influencing control of Supernus, indicating a passive investment stance.
Supernus Pharmaceuticals, Inc. reported that on January 22, 2026 it entered into a First Amendment to its September 12, 2018 Agreement and Plan of Merger, with Reich Consulting Group, Inc. acting as Securityholder Representative.
The amendment changes the timing and payment of certain merger-related milestones. Supernus is filing the amendment as Exhibit 10.1, with limited portions omitted as confidential under Regulation S-K Item 601(b)(10)(iv), which the company states are not material and would be competitively harmful if publicly disclosed.
Dimensional Fund Advisors LP reports beneficial ownership of 2,712,341 shares of Supernus Pharmaceuticals Inc common stock, representing 4.7% of the class as of 12/31/2025, in an amended Schedule 13G filing. Dimensional has sole power to vote 2,650,157 shares and sole power to dispose of 2,712,341 shares.
The shares are owned by various investment companies, commingled funds, group trusts, and separate accounts advised or sub-advised by Dimensional or its subsidiaries, which are collectively referred to as the Funds. Dimensional may be deemed a beneficial owner for Section 13(d) purposes but expressly disclaims beneficial ownership, noting that all securities are owned by the Funds and that no single Fund is known to hold 5% or more of the class. Dimensional certifies that the holdings are in the ordinary course of business and not for the purpose of changing or influencing control of Supernus.
Supernus Pharmaceuticals director Hudson Frederick M. reported an option exercise and share acquisition. On January 9, 2026, he exercised a director stock option to buy 15,000 shares of common stock at an exercise price of $12.98 per share. The corresponding derivative position, a director stock option granted on March 1, 2017 and expiring on March 1, 2026, was reduced by 15,000 options to 0 following the transaction.
As a result of this option exercise, Hudson Frederick M. now directly owns 61,307 shares of Supernus Pharmaceuticals common stock. The filing classifies all reported holdings as directly owned, with no indirect ownership structures noted in the data provided.